DE60217854D1 - Herstellung von agonisten und antagonisten von cholecystokinin und ihre therapeutische und diagnostische verwendung - Google Patents

Herstellung von agonisten und antagonisten von cholecystokinin und ihre therapeutische und diagnostische verwendung

Info

Publication number
DE60217854D1
DE60217854D1 DE60217854T DE60217854T DE60217854D1 DE 60217854 D1 DE60217854 D1 DE 60217854D1 DE 60217854 T DE60217854 T DE 60217854T DE 60217854 T DE60217854 T DE 60217854T DE 60217854 D1 DE60217854 D1 DE 60217854D1
Authority
DE
Germany
Prior art keywords
antagonists
preparation
agonists
therapeutic
cholecystinkin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60217854T
Other languages
English (en)
Other versions
DE60217854T2 (de
Inventor
Michele Saviano
Luca Stefania De
Giancarlo Morelli
Diego Tesauro
Carlo Pedone
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bracco Imaging SpA
Original Assignee
Bracco Imaging SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bracco Imaging SpA filed Critical Bracco Imaging SpA
Application granted granted Critical
Publication of DE60217854D1 publication Critical patent/DE60217854D1/de
Publication of DE60217854T2 publication Critical patent/DE60217854T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/595—Gastrins; Cholecystokinins [CCK]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/534—Production of labelled immunochemicals with radioactive label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
DE60217854T 2001-05-22 2002-05-21 Herstellung von agonisten und antagonisten von cholecystokinin und ihre therapeutische und diagnostische verwendung Expired - Lifetime DE60217854T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT2001MI001057A ITMI20011057A1 (it) 2001-05-22 2001-05-22 Preparazione ed uso di peptidi ciclici e ramificati e loro deriati marcati come agenti terapeutici agonisti o antagonisti della colecistochi
ITMI20011057 2001-05-22
PCT/EP2002/005562 WO2002094873A2 (en) 2001-05-22 2002-05-21 Preparation of cholecystokinin agonists and antagonists, and their therapeutic and diagnostic use

Publications (2)

Publication Number Publication Date
DE60217854D1 true DE60217854D1 (de) 2007-03-15
DE60217854T2 DE60217854T2 (de) 2007-11-15

Family

ID=11447707

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60217854T Expired - Lifetime DE60217854T2 (de) 2001-05-22 2002-05-21 Herstellung von agonisten und antagonisten von cholecystokinin und ihre therapeutische und diagnostische verwendung

Country Status (8)

Country Link
US (1) US7329644B2 (de)
EP (1) EP1390405B1 (de)
JP (1) JP4264263B2 (de)
AT (1) ATE352567T1 (de)
AU (1) AU2002339007A1 (de)
DE (1) DE60217854T2 (de)
IT (1) ITMI20011057A1 (de)
WO (1) WO2002094873A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050260259A1 (en) * 2004-04-23 2005-11-24 Bolotin Elijah M Compositions for treatment with glucagon-like peptide, and methods of making and using the same
US7138105B2 (en) * 2002-02-27 2006-11-21 Pharmain Compositions for delivery of therapeutics and other materials, and methods of making and using the same
US7635463B2 (en) 2002-02-27 2009-12-22 Pharmain Corporation Compositions for delivery of therapeutics and other materials
WO2006128643A2 (en) * 2005-05-31 2006-12-07 Inbios S.R.L. Supramolecular aggregates containing chelating agents and bioactive peptides as effective and selective delivery tools for drugs and contrast agents in mri or nuclear medicine
US8986650B2 (en) 2005-10-07 2015-03-24 Guerbet Complex folate-NOTA-Ga68
EP1940841B9 (de) 2005-10-07 2017-04-19 Guerbet Verbindungen mit einem eine biologische zielstruktur erkennenden teil, das mit einem zum komplexieren von gallium fähigen signalteil gekoppelt ist
KR101687037B1 (ko) 2008-06-09 2016-12-15 팔라틴 테크놀로지스 인코포레이티드 성기능 장애 치료용 멜라노코르틴 수용체-특이적 펩티드
DE102008060549A1 (de) 2008-12-04 2010-06-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung
FR2942227B1 (fr) 2009-02-13 2011-04-15 Guerbet Sa Utilisation de tampons pour la complexation de radionucleides
UY32690A (es) 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
EA201290295A1 (ru) 2009-11-23 2013-01-30 Палатин Текнолоджиз, Инк. Специфичные к рецептору меланокортина-1 линейные пептиды
NZ599774A (en) 2009-11-23 2014-11-28 Palatin Technologies Inc Melanocortin-1 receptor-specific cyclic peptides
US8986651B2 (en) 2009-11-30 2015-03-24 Stc.Unm Compounds with reduced ring size for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same
FR2968999B1 (fr) 2010-12-20 2013-01-04 Guerbet Sa Nanoemulsion de chelate pour irm
FR2980364B1 (fr) 2011-09-26 2018-08-31 Guerbet Nanoemulsions et leur utilisation comme agents de contraste
FR3001154B1 (fr) 2013-01-23 2015-06-26 Guerbet Sa Magneto-emulsion vectorisee
US11110063B2 (en) 2017-08-25 2021-09-07 MAIA Pharmaceuticals, Inc. Storage stable sincalide formulations
WO2020007822A1 (en) 2018-07-02 2020-01-09 Conservatoire National Des Arts Et Metiers (Cnam) Bismuth metallic (0) nanoparticles, process of manufacturing and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE276482C (de)
DD276482B5 (de) * 1988-10-25 1996-08-08 Charite Med Fakultaet Verfahren zur Herstellung neuer Cholecystokininsequenzen
GB9107566D0 (en) 1991-04-10 1991-05-29 Ludwig Inst Cancer Res Glial mitogenic factors,their preparation and use
WO1997044341A1 (en) * 1996-05-17 1997-11-27 Rotta Research Laboratorium S.P.A. Cyclic polyamides of glutamic acid and aspartic acid with anti-gastrin activity, a method for their preparation and their pharmaceutical use
CA2263784A1 (en) * 1998-03-23 1999-09-23 Megabios Corporation Dual-tagged proteins and their uses

Also Published As

Publication number Publication date
WO2002094873A2 (en) 2002-11-28
US20040254339A1 (en) 2004-12-16
JP4264263B2 (ja) 2009-05-13
DE60217854T2 (de) 2007-11-15
US7329644B2 (en) 2008-02-12
EP1390405A2 (de) 2004-02-25
WO2002094873A3 (en) 2003-07-24
EP1390405B1 (de) 2007-01-24
JP2005503350A (ja) 2005-02-03
AU2002339007A1 (en) 2002-12-03
ITMI20011057A0 (it) 2001-05-22
ITMI20011057A1 (it) 2002-11-22
ATE352567T1 (de) 2007-02-15

Similar Documents

Publication Publication Date Title
ATE352567T1 (de) Herstellung von agonisten und antagonisten von cholecystokinin und ihre therapeutische und diagnostische verwendung
CY1109886T1 (el) Καινοφανεις ενωσεις ως αντι-φλεγμονωδεις, ανοσοτροποποιητικοι και αντι υπερπλαστικοι παραγοντες
DK1648925T3 (da) Bicyklisk peptid-billeddannende midler
EA200101177A1 (ru) Производные индола в качестве антагонистов прогестерона
EA200300829A1 (ru) Производные 1-арил- или 1-алкилсульфонилбензазола в качестве лигандов 5-гидрокситриптамина-6
BR0206595A (pt) Composto, composição farmacêutica, e uso de um composto
NO20024932D0 (no) Kontrastmiddel
CY1105386T1 (el) Βενζοϋλοσουλφοναμιδια και σουλφονυλβενζαμιδινες για χρηση σαν παραγοντες κατα του ογκου
DE60222396D1 (de) N-(2-arylethyl) benzylamine als 5-ht6 rezeptor-antagoniste
MXPA04000173A (es) Compuestos basados en peptidos.
EA200200530A1 (ru) Гетероциклические замещенные пиразолоны
DK0640592T3 (da) N-acylerede tricycliske azaheteroringe anvendelige som vasopressin-antagonister
CY1106247T1 (el) Θειοφαινο- και θειαζολοσουλφοναμιδες ως αντινεοπλαστικοι παραγοντες
EA200301215A1 (ru) Лиганды рецепторов 5-ht и их применение
EA200101046A1 (ru) Производные индигоидных бис-индолов
BR9911621A (pt) Bifenil sulfonamidas como antagonista duplos de receptor de angiotensina endotelina
EA200401526A1 (ru) Новые соединения и их применение
EA200300716A1 (ru) Гетероциклилалкилиндольные или -азаиндольные соединения в качестве лиганд 5-гидрокситриптамина-6
MA27501A1 (fr) Derives d'imidazoquinoline en tant que ligands recepteurs de l'adenosine a3
DE60206272D1 (de) Chelatorkonjugate mit verbesserten eigenschaften
ATE345355T1 (de) Peptidkonjugate, deren derivate mit metallischen komplexen und deren verwendung zur bildgebenden magnetischen resonanz
EA200301143A1 (ru) Производные гетероциклилалкокси-, алкилтио- и -алкиламинобензазола в качестве лигандов 5-гидрокситриптамина-6
BR0212353A (pt) Composto, composição farmacêutica, e, uso de um composto
EA200501341A1 (ru) Противобактериальные индолоноксазолидиноны, промежуточные соединения для их получения и содержащие их фармацевтические композиции
EA200100517A1 (ru) Антагонисты 5ht1 для антидепрессантной терапии

Legal Events

Date Code Title Description
8364 No opposition during term of opposition